Irbesartan in the regression of left ventricular hypertrophy

被引：0
|
作者：
Malmqvist, K [1 ]
Kahan, T [1 ]
Edner, M [1 ]
Held, C [1 ]
Osbakken, M [1 ]
机构：
[1] Karolinska Inst, Danderyd Hosp, Div Internal Med, S-18288 Danderyd, Sweden
来源：
XIII WORLD CONGRESS OF CARDIOLOGY: FREE PAPERS | 1998年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Left ventricular hypertrophy (LVH) is a major independent risk factor for cardiovascular disease and a significant independent predictor of mortality (Sullivan et ai, 1993). The effects of irbesartan (IRBE) on the regression of left ventricular hypertrophy (LVH) were compared to those of atenolol (ATN) in a double-blind, 48-week study. Despite similar reductions in blood pressure (BP), LVH regressed sooner and to a greater degree with IRBE compared with ATN. Thus, IRBE produced superior end organ protection with better tolerability.
引用
收藏
页码：427 / 431
页数：5
相关论文
共 50 条
  • [21] Ageing and regression of left ventricular hypertrophy.
    Du Cailar, G
    Ribstein, J
    Mimran, A
    REVUE DE MEDECINE INTERNE, 1998, 19 (12): : 870 - 877
  • [22] REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY - A METAANALYSIS
    DAHLOF, B
    PENNERT, K
    HANSSON, L
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1992, 14 (1-2) : 173 - 180
  • [23] Renal denervation and regression of left ventricular hypertrophy
    Bruno, Rosa Maria
    Taddei, Stefano
    EUROPEAN HEART JOURNAL, 2014, 35 (33) : 2205 - 2207
  • [24] Regression of left ventricular hypertrophy by inhibition of mTOR
    Gao, XM
    Wong, G
    Wang, B
    Kiriazis, H
    Moore, S
    Su, YD
    Xu, Q
    Du, XJ
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 39 (03) : 572 - 572
  • [25] DEVELOPMENT AND REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY
    PANIDIS, IP
    KOTLER, MN
    REN, JF
    MINTZ, GS
    ROSS, J
    KALMAN, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1984, 3 (05) : 1309 - 1320
  • [26] Regression of left ventricular hypertrophy: Are there preferred drugs?
    Joseph A. Diamond
    Robert A. Phillips
    Current Hypertension Reports, 2003, 5 : 368 - 371
  • [27] Central obesity and left ventricular hypertrophy regression
    Piskorz, Daniel
    Citta, Luciano
    Citta, Norberto
    Lanzotti, Marcelo
    Lanzotti, Roberto
    Locatelli, Horacio
    Tommasi, Alicia
    INSUFICIENCIA CARDIACA, 2007, 2 (04) : 159 - 162
  • [28] Prognostic significance of left ventricular hypertrophy regression
    Agabiti-Rosei, E
    Muiesan, ML
    HYPERTENSION AND THE HEART, 1997, 432 : 199 - 205
  • [29] Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial)
    A Cohen
    B Bregman
    E Agabiti Rosei
    B Williams
    O Dubourg
    P Clairefond
    P Brudi
    P Gosse
    P Guéret
    Journal of Human Hypertension, 1998, 12 : 479 - 483
  • [30] Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial)
    Cohen, A
    Bregman, B
    Rosei, EA
    Williams, B
    Dubourg, O
    Clairefond, P
    Brudi, P
    Gosse, P
    Gueret, P
    JOURNAL OF HUMAN HYPERTENSION, 1998, 12 (07) : 479 - 483
12345